Trial reportPharmacogenetics and genomics2009
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.
Trial report in Pharmacogenetics and genomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.PloS one · 2012Pooled it
- Cost effectiveness of pharmacogenomics: a critical and systematic review.PharmacoEconomics · 2010Pooled it
- Effect of gene polymorphism on bleeding complications in Chinese Han patients taking warfarin.European journal of clinical pharmacology · 2022Article
- Pharmacogenetics of Praziquantel Metabolism: Evaluating the Cytochrome P450 Genes of Zimbabwean Patients During a Schistosomiasis Treatment.Frontiers in genetics · 2022Article
- Profiling of warfarin pharmacokinetics-associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics-dosing algorithm.Journal of thrombosis and haemostasis : JTH · 2021Article
- Drug Response Pharmacogenetics for 200,000 UK Biobank Participants.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2021Article
- Article
- The Clinical Pharmacokinetics and Pharmacodynamics of Warfarin When Combined with Compound Danshen: A Case Study for Combined Treatment of Coronary Heart Diseases with Atrial Fibrillation.Frontiers in pharmacology · 2017Article
- Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study.Frontiers in pharmacology · 2017Article
- Effect of Genetic Variability in theFrontiers in pharmacology · 2017Article
- A multi-factorial analysis of response to warfarin in a UK prospective cohort.Genome medicine · 2016Article
- CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.European journal of clinical pharmacology · 2015Article
- Factors affecting time to maintenance dose in patients initiating warfarin.Pharmacoepidemiology and drug safety · 2015Article
- Genome-wide association study of warfarin maintenance dose in a Brazilian sample.Pharmacogenomics · 2015Article
- Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.Archives of biochemistry and biophysics · 2014Article
- Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.The pharmacogenomics journal · 2014Article
- Review
- What is the Best Treatment for a Cancer Patient with Thrombosis?Clinical Medicine Insights. Oncology · 2014Review
- Development of a chiral micellar electrokinetic chromatography-tandem mass spectrometry assay for simultaneous analysis of warfarin and hydroxywarfarin metabolites: application to the analysis of patients serum samples.Journal of chromatography. A · 2013Article
- Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.International journal of hematology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundIn this prospective cohort study, we have undertaken a comprehensive evaluation of clinical parameters along with variation in 29 genes (including CYP2C9 and VKORC1) to identify factors determining interindividual variability in warfarin response.
methodsConsecutive patients (n=311) were followed up prospectively for 26 weeks. Several outcomes chosen to capture both warfarin efficacy and toxicity were assessed. Univariate and multiple regression analyses were undertaken to assess the combined effect of clinical and genetic factors.
resultsCYP2C9 was the most important gene determining initial anticoagulant control, whereas VKORC1 was more important for stable anticoagulation. Novel associations with some clinical outcomes were found with single nucleotide polymorphisms in the cytochrome 450 genes CYP2C18 and CYP2C19, which were independent of the associations observed with CYP2C9 and in genes encoding CYP3A5, protein S and clotting factor V, although the variability explained by these genes was small. On the basis of the results of microcosting, adverse events were shown to be a significant predictor of total cost.
conclusionAccurate prediction of warfarin dose requirement needs to take into account multiple genetic and environmental factors, the contributions of which vary in the induction and maintenance phases of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.